Visiopharm Welcomes Dirk Vossen as Chief Diagnostics Officer

Visiopharm is pleased to announce that Dirk Vossen Ph.D. has joined the company as its new Chief Diagnostics Officer.

Dirk brings extensive experience as a global leader in digital pathology, specialized in cancer tissue diagnostics and clinical workflows. His track record of creating value through innovation in digital and computational pathology spans the entire range of development, from ideation through validation and certification of medical devices, as well as commercialization strategies.

Based in The Netherlands, Dirk will be leading Visiopharm’s clinical diagnostics programs, with cross-functional responsibilities that support the company’s continued expansion into diagnostic and clinical applications of digital pathology.

“I have worked with Dirk as a partner, and have admired not only his deep understanding of the digital pathology market, but his innovative leadership and drive to create solutions that propel the industry forward and ultimately improve the care that cancer patients receive,” says Michael Grunkin Ph.D., CEO, and co-founder of Visiopharm. “That’s why I am delighted to welcome him to Visiopharm and look forward to his contributions as we continue on our journey to create precision pathology solutions that elevate the industry standards for diagnostic and clinical image analysis.”

As the co-founder of Philips Digital and Computational Pathology business, Dirk brings over a decade of experience in building digital pathology solutions, including the development of whole slide image scanners, image management systems, computational pathology applications as well as driving the strategies and execution of clinical programs. A key addition to the management team, Dirk will orchestrate the successful development and commercialization of clinical products that put the latest advances in tissue mining into the hands of pathologists.

“It’s an extraordinary time to join Visiopharm, with digital pathology becoming mainstream and breakthrough AI applications that will elevate the quality of data that pathologists use to make critical decisions for patients,” he said. “I am eager to be a part of this next phase of the company’s growth.”